Home Journals Articles Updates About
CN
image
收藏切换
Why did FDA grant Zanubrutinib breakthrough designation for mantle cell lymphoma?
收藏切换
PDF
Science & Technology Review | 2019, 37(11) : 6 - 8
Less
收藏切换
Science & Technology Review | 2019, 37(11): 6-8
• Scientific Comments •
Why did FDA grant Zanubrutinib breakthrough designation for mantle cell lymphoma?
Full
ZHANG Hongtao
Affiliations
    Pathology and Laboratory Medicine, Perelman School of Medicine, Philadelphia 19104, USA
Published: 2019-06-13 doi: 10.3981/j.issn.1000-7857.2019.11.001
Outline
收藏切换
The U.S. Food and Drug Administration (FDA) has granted the investigational BTK inhibitor Zanubrutinib (BGB-3111) a breakthrough therapy designation for the treatment of adult patients with mantle cell lymphoma (MCL) who have previously received at least 1 prior therapy, on Jan. 15th 2019. This paper introduced the definition of the breakthrough therapy designation, the breakthrough achievements of Zanubrutinib, the significance of this event to Chinese pharmaceutical R&D enterprises.
breakthrough designation  /  anticancer drugs  /  Zanubrutinib
张洪涛. 中国第一个获得美国FDA“突破性疗法”认证的抗癌新药，到底好在哪?. 科技导报, 2019 , 37 (11) : 6 -8 . DOI: 10.3981/j.issn.1000-7857.2019.11.001
ZHANG Hongtao. Why did FDA grant Zanubrutinib breakthrough designation for mantle cell lymphoma?[J]. Science & Technology Review, 2019 , 37 (11) : 6 -8 . DOI: 10.3981/j.issn.1000-7857.2019.11.001
Appendix
Less
Year 2019 volume 37 Issue 11
PDF
595
157
Cite this Article
BibTeX
Article Info
doi: 10.3981/j.issn.1000-7857.2019.11.001
  • Receive Date：2019-01-28
  • Online Date：2019-06-20
  • Published：2019-06-13
Article Data
Affiliations
History
  • Received：2019-01-28
  • Revised：2019-02-05
Affiliations
References
Share
https://castjournals.cast.org.cn/joweb/kjdb/EN/10.3981/j.issn.1000-7857.2019.11.001
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House